Bayer Reports Topline Data from P-III (QUANTI) Trials of Gadoquatrane for its Use in MRI
Shots:
- The P-III (QUANTI; N=808) trials of gadoquatrane (0.04mmol Gd/kg body wt.) comprised of QUANTI CNS for CNS disorders like brain tumors, brain metastasis & multiple sclerosis; QUANTI OBR for other body regions like head & neck, thorax, abdomen & pelvis as well as QUANTI Pediatric study for children (birth to 18yrs.)
- Study assessed gadoquatrane vs macrocyclic GBCAs (0.1mmol Gd/kg body wt.) & scans without contrast injection for its use in MRI. It achieved all the EPs of visualization & lesion detection, with similar PK profile in children
- Safety aligned with prior data without any new concerns. Bayer will share a comprehensive data package incl. above findings with the regulatory bodies globally for approval
Ref: Bayer | Image: Bayer
Related News:- Bayer Reports the US FDA’s sNDA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
